Xvivo Perfusion AB (LTS:0RKL) E10: kr1.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKL Xvivo Perfusion AB LTS:0RKL
84 GF Score
Price kr235.11
GF Value kr397.30
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB E10?

Xvivo Perfusion AB LTS:0RKL -9.09% 84 E10 is kr1.11 as of Jun. 2026. GuruFocus rates LTS:0RKL with a GF Score™ of 84/100 and a GF Value™ of kr397.30 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xvivo Perfusion AB's adjusted earnings per share data for the three months ended in Jun. 2026 was kr0.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr1.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xvivo Perfusion AB's average E10 Growth Rate was -100.00% per year. During the past 3 years, the average E10 Growth Rate was 90.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Xvivo Perfusion AB was 90.00% per year. The lowest was 90.00% per year. And the median was 90.00% per year.

As of today (2026-07-16), Xvivo Perfusion AB's current stock price is kr235.112. Xvivo Perfusion AB's E10 for the quarter that ended in Jun. 2026 was kr1.11. Xvivo Perfusion AB's Shiller PE Ratio of today is 211.81.

During the past 13 years, the highest Shiller PE Ratio of Xvivo Perfusion AB was 1814.29. The lowest was 186.48. And the median was 707.05.


Xvivo Perfusion AB  (LTS:0RKL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xvivo Perfusion AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=235.112/1.11
=211.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Xvivo Perfusion AB was 1814.29. The lowest was 186.48. And the median was 707.05.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xvivo Perfusion AB E10 Related Terms


Xvivo Perfusion AB E10 Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB E10 Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.14 0.39 0.91 0.95

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.89 0.95 1.07 1.11

LTS:0RKL vs ABT, SYK, MDT: E10 Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Shiller PE Ratio falls into.


LTS:0RKL
84GF Score
Xvivo Perfusion AB LTS:0RKL
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.52/134.1100*134.1100
=0.520

Current CPI (Jun. 2026) = 134.1100.

Xvivo Perfusion AB Quarterly Data

per share eps CPI Adj_EPS
201609 -0.020 101.138 -0.027
201612 -0.020 102.022 -0.026
201703 -0.002 102.022 -0.003
201706 0.040 102.752 0.052
201709 -0.010 103.279 -0.013
201712 0.210 103.793 0.271
201803 0.150 103.962 0.193
201806 0.150 104.875 0.192
201809 0.004 105.679 0.005
201812 0.180 105.912 0.228
201903 -0.010 105.886 -0.013
201906 0.080 106.742 0.101
201909 0.180 107.214 0.225
201912 -0.080 107.766 -0.100
202003 0.250 106.563 0.315
202006 -0.600 107.498 -0.749
202009 -0.510 107.635 -0.635
202012 -0.700 108.296 -0.867
202103 0.200 108.360 0.248
202106 -0.310 108.928 -0.382
202109 -0.040 110.338 -0.049
202112 0.420 112.486 0.501
202203 0.160 114.825 0.187
202206 0.260 118.384 0.295
202209 0.180 122.296 0.197
202212 0.020 126.365 0.021
202303 0.480 127.042 0.507
202306 0.230 129.407 0.238
202309 0.080 130.224 0.082
202312 2.170 131.912 2.206
202403 0.720 132.205 0.730
202406 0.860 132.716 0.869
202409 2.710 132.304 2.747
202412 1.150 132.987 1.160
202503 -0.390 132.825 -0.394
202506 0.050 133.699 0.050
202509 0.140 133.480 0.141
202512 1.010 133.390 1.015
202603 1.150 133.560 1.155
202606 0.520 134.110 0.520

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr1.11 mean?
Xvivo Perfusion AB (LTS:0RKL) has a E10 of kr1.11 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's E10 too high?
Xvivo Perfusion AB's current E10 is kr1.11. Overall, Xvivo Perfusion AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's E10 compare to ABT and SYK?
Xvivo Perfusion AB's E10 of kr1.11 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current E10 is kr1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (LTS:0RKL) is currently considered Significantly Undervalued. The stock's GF Value™ is kr397.30, compared to a current price of kr235.11 — trading 40.8% below its estimated fair value. The current E10 is kr1.11. Xvivo Perfusion AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Xvivo Perfusion AB (LTS:0RKL), the current E10 is kr1.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (LTS:0RKL) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr235.11 is trading 40.8% below its estimated GF Value™ of kr397.30. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for LTS:0RKL:

  • E10: kr1.11
  • GF Value™: kr397.30 vs. price of kr235.11 (40.8% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
84GF Score

Get the complete analysis for LTS:0RKL

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr235.11
Price
kr397.30
GF Value